FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048206003> ?p ?o ?g. }

• W3048206003 endingPage "1784" @default.
• W3048206003 startingPage "1784" @default.
• W3048206003 abstract "Abstract Background: Response criteria in myeloma have been developed to predict treatment outcome and to compare results from clinical trials. The current IMWG response criteria (Kumar, Lancet Oncology 2016) are based on paraprotein assessment by immunofixation and electrophoresis of serum and urine. The hevylite (HLC) assay directly quantifies the kappa and lambda fractions of IgG, IgA and IgM as well as the corresponding kappa/lambda ratios. To compare the response assessment by IMWG criteria and by HLC we applied the test to serum samples from the prospective GMMG MM5 trial in newly diagnosed myeloma patients. Patients and Methods: 502 transplant-eligible myeloma patients were randomised to induction with bortezomib/dexamethasone combined to either adriamycin or cyclophosphamide and to receive either continuous or response-adapted lenalidomide maintenance. After 3 cycles stem cells were collected and high-dose melphalan and autologous stem cell transplantation (HDT) was performed. Patients not in nCR or CR were planned to receive a second HDT. All patients received 2 cycles of lenalidomide consolidation followed by lenalidomide maintenance according to the initial randomisation. After each treatment phase response was assessed according to IMWG. Frozen serum samples from the same time points were used to perform the HLC test. The current analysis is focused on the response after induction and after the first HDT in patients with either IgA or IgG paraprotein. To quantify the paraprotein by HLC the difference between involved and uninvolved HLC was calculated and the ratio HLC difference after treatment/HLC difference at baseline was used as response parameter. HLC responses were defined as HLC-CR (normal HLC kappa/lambda ratio,IgA: 0.78-1.94, IgG: 1.12-3.21), HLC-VGPR (≥ 90% reduction in HLC difference), HLC-PR (between 50% and 89% reduction), HLC-SD (49% reduction to 24% increase) or HLC-PD (≥ 25% increase). Results: Of the 502 patients 105 had IgA and 298 IgG paraprotein. Sufficient serum samples to assess HLC-responses were available for 292 (IgA: 86, IgG: 212) patients.), 18% had HLC-CR, 23% HLC-VGPR and 41% HLC-PR after induction, while IMWG-based responses were 4% CR, 13% nCR, 15% VGPR and 49% PR. Overall there was a moderate concordance between both assessments: Of 205 patients achieving at least a PR, 191 (93%) also had at least HLC-PR. For 81 patients with ≥ VGPR, 69 had ≥HLC-VGPR (85%). Conversely, of 207 patients with ≥ HLC-PR 161 (78%) showed ≥ PR by IMWG and 104 patients with ≥ HLC-VGPR 69 (66%) had ≥VGPR. After first HDT the IMWG-responses were 18% CR, 22% nCR, 19% VGPR and 35% PR, while HLC yielded 50% HLC-CR, 24% HLC-VGPR and 18% HLC-PR. Of 214 patients with ≥ PR 201 had ≥ HLC-PR (94%), while of 134 patients with ≥ VGPR, 121 had ≥HLC-VGPR (90%). Of 169 patients with ≥ HLC VGPR 121 (72%) had ≥VGPR and ≥PR was found in 158/211 patients with ≥ HLC-PR (75%). To assess the prognostic value of both response assessments Kaplan-Meier landmark analyses of progression-free survival (PFS) and overall survival (OS) at 6 months for induction and 9 months for HDT were performed. CR and nCR after induction were associated with a better PFS than the other response categories (log-rank test: p Conclusions: Our results show that HLC for IgA and IgG can identify patients achieving ≥PR and ≥ VGPR according to IMWG after induction and after HDT in newly diagnosed myeloma patients. HLC response categories were not correlated with PFS, however HLC-CR after induction identified a subgroup of patients with an excellent overall survival of 88% at 5 years. Further analyses will elucidate this finding by including MRD results and genetic risk factors. Disclosures Scheid: BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria. Durig: Lead Discovery Center: Research Funding. Weisel: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Munder: Consultancy: Janssen-Cilag, BMS, Takeda, Amgen, Celgene.: Consultancy; Celgene: Consultancy; Amgen: Consultancy; BMS: Consultancy; Takeda: Consultancy. Mai: Janssen: Honoraria, Other: Travel grants; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Other: Travel grants; Mundipharma: Other: Travel grants; Onyx: Other: Travel grants. Hillengass: honoraria from Amgen, BMS, Celgene: Honoraria; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria. Raab: Novartis: Consultancy, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria; BMS: Consultancy, Speakers Bureau. Hose: Takeda: Membership on an entity's Board of Directors or advisory committees; Sanofi: Research Funding; EngMab: Research Funding. Goldschmidt: Morphosys: Research Funding; Onyx: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Chugai: Consultancy, Honoraria, Research Funding, Speakers Bureau; Millenium: Research Funding, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Salwender: Takeda: Honoraria; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Honoraria and travel support: Janssen Cilag, Celgene, BMS.: Honoraria, Other: Travel support." @default.
• W3048206003 created "2020-08-13" @default.
• W3048206003 creator A5002288518 @default.
• W3048206003 creator A5003185875 @default.
• W3048206003 creator A5005029408 @default.
• W3048206003 creator A5007067641 @default.
• W3048206003 creator A5009950958 @default.
• W3048206003 creator A5010225556 @default.
• W3048206003 creator A5014277422 @default.
• W3048206003 creator A5015972472 @default.
• W3048206003 creator A5019564821 @default.
• W3048206003 creator A5019570679 @default.
• W3048206003 creator A5022522496 @default.
• W3048206003 creator A5025442371 @default.
• W3048206003 creator A5036936763 @default.
• W3048206003 creator A5039853793 @default.
• W3048206003 creator A5041374198 @default.
• W3048206003 creator A5048499083 @default.
• W3048206003 creator A5054649040 @default.
• W3048206003 creator A5055916434 @default.
• W3048206003 creator A5056743174 @default.
• W3048206003 creator A5059718263 @default.
• W3048206003 creator A5060295441 @default.
• W3048206003 creator A5064702344 @default.
• W3048206003 creator A5065363681 @default.
• W3048206003 creator A5067657650 @default.
• W3048206003 creator A5068472643 @default.
• W3048206003 creator A5087348033 @default.
• W3048206003 date "2017-12-07" @default.
• W3048206003 modified "2023-10-03" @default.
• W3048206003 title "Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial" @default.
• W3048206003 doi "https://doi.org/10.1182/blood.v130.suppl_1.1784.1784" @default.
• W3048206003 hasPublicationYear "2017" @default.
• W3048206003 type Work @default.
• W3048206003 sameAs 3048206003 @default.
• W3048206003 citedByCount "0" @default.
• W3048206003 crossrefType "journal-article" @default.
• W3048206003 hasAuthorship W3048206003A5002288518 @default.
• W3048206003 hasAuthorship W3048206003A5003185875 @default.
• W3048206003 hasAuthorship W3048206003A5005029408 @default.
• W3048206003 hasAuthorship W3048206003A5007067641 @default.
• W3048206003 hasAuthorship W3048206003A5009950958 @default.
• W3048206003 hasAuthorship W3048206003A5010225556 @default.
• W3048206003 hasAuthorship W3048206003A5014277422 @default.
• W3048206003 hasAuthorship W3048206003A5015972472 @default.
• W3048206003 hasAuthorship W3048206003A5019564821 @default.
• W3048206003 hasAuthorship W3048206003A5019570679 @default.
• W3048206003 hasAuthorship W3048206003A5022522496 @default.
• W3048206003 hasAuthorship W3048206003A5025442371 @default.
• W3048206003 hasAuthorship W3048206003A5036936763 @default.
• W3048206003 hasAuthorship W3048206003A5039853793 @default.
• W3048206003 hasAuthorship W3048206003A5041374198 @default.
• W3048206003 hasAuthorship W3048206003A5048499083 @default.
• W3048206003 hasAuthorship W3048206003A5054649040 @default.
• W3048206003 hasAuthorship W3048206003A5055916434 @default.
• W3048206003 hasAuthorship W3048206003A5056743174 @default.
• W3048206003 hasAuthorship W3048206003A5059718263 @default.
• W3048206003 hasAuthorship W3048206003A5060295441 @default.
• W3048206003 hasAuthorship W3048206003A5064702344 @default.
• W3048206003 hasAuthorship W3048206003A5065363681 @default.
• W3048206003 hasAuthorship W3048206003A5067657650 @default.
• W3048206003 hasAuthorship W3048206003A5068472643 @default.
• W3048206003 hasAuthorship W3048206003A5087348033 @default.
• W3048206003 hasConcept C126322002 @default.
• W3048206003 hasConcept C143998085 @default.
• W3048206003 hasConcept C188816634 @default.
• W3048206003 hasConcept C203014093 @default.
• W3048206003 hasConcept C2776364478 @default.
• W3048206003 hasConcept C2780739268 @default.
• W3048206003 hasConcept C2911091166 @default.
• W3048206003 hasConcept C3019894029 @default.
• W3048206003 hasConcept C71924100 @default.
• W3048206003 hasConceptScore W3048206003C126322002 @default.
• W3048206003 hasConceptScore W3048206003C143998085 @default.
• W3048206003 hasConceptScore W3048206003C188816634 @default.
• W3048206003 hasConceptScore W3048206003C203014093 @default.
• W3048206003 hasConceptScore W3048206003C2776364478 @default.
• W3048206003 hasConceptScore W3048206003C2780739268 @default.
• W3048206003 hasConceptScore W3048206003C2911091166 @default.
• W3048206003 hasConceptScore W3048206003C3019894029 @default.
• W3048206003 hasConceptScore W3048206003C71924100 @default.
• W3048206003 hasLocation W30482060031 @default.
• W3048206003 hasOpenAccess W3048206003 @default.
• W3048206003 hasPrimaryLocation W30482060031 @default.
• W3048206003 hasRelatedWork W2576841436 @default.
• W3048206003 hasRelatedWork W2582805007 @default.
• W3048206003 hasRelatedWork W2591350172 @default.
• W3048206003 hasRelatedWork W2593675088 @default.
• W3048206003 hasRelatedWork W2777718526 @default.
• W3048206003 hasRelatedWork W2784400197 @default.
• W3048206003 hasRelatedWork W2785025237 @default.
• W3048206003 hasRelatedWork W2793654381 @default.
• W3048206003 hasRelatedWork W2803417376 @default.
• W3048206003 hasRelatedWork W2911003649 @default.
• W3048206003 hasRelatedWork W2914922594 @default.
• W3048206003 hasRelatedWork W2924248521 @default.
• W3048206003 hasRelatedWork W2969955865 @default.
• W3048206003 hasRelatedWork W2971950827 @default.

• next